Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2009

View Archived Issues

Budesonide fails to prevent ipilimumab-induced diarrhea in advanced melanoma patients

Dainippon Sumitomo Pharma reports results from Q1 ending June 30, 2009

Novel MAP kinase p38 inhibitor effective in rat models of arthritis

Novel GlaxoSmithKline agents activate SIRT1

Bayer describes novel phosphatidylinositol 3-kinase inhibitors

French scientists disclose bisphosphonate-based vectors for targeting bone tissue

Orexo and Novartis sign exclusive worldwide licensing agreement for OX-17-related product

Arno initiates dosing in phase I clinical study of PDK1 inhibitor AR-12 in cancer

Biotie Therapies reaches milestone in Wyeth collaboration for PDE10 inhibitors for schizophrenia

Clinical trials of GAI-122 for prevention of delirium expected to begin by mid-2010

IDRI initiates phase I clinical trial of leishmaniasis vaccine candidate

Hisamitsu acquires Noven

Taisho developing mGlu5 receptor antagonists for anxiety

Novel ZAP-70 inhibitors reported to be in early development at Cellzome

Dainippon Sumitomo Pharma patents DPP IV inhibitors for diabetes

REG1 system induces controlled anticoagulation in phase IIa study in PCI patients

Research collaboration identifies possible new treatments for human African trypanosomiasis

Compounds inhibiting PI3 kinase designed by Wyeth for treating cancer

Facet Biotech and Trubion sign collaboration agreement for TRU-016 in CLL

Innate Pharma granted approval to initiate phase IIa trial of IPH-2101 for multiple myeloma

Health Canada approves Medicago's CTA for phase I human clinical trial of H5N1 vaccine

Takeda initiates EXAMINE cardiovascular outcomes trial of alogliptin for diabetes

Stallergenes names second sublingual desensitization tablet

Valcyte approved for prevention of CMV in pediatric transplant patients

RE-LY study reveals advantage of dabigatran over warfarin in atrial fibrillation patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...